Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard

Anti-Cancer Drug Design

Volumn 13, Issue 8, 1998, Pages 995-1007

  Lougerstay Madec, Rachel ^a   Florent, Jean Claude ^a   Monneret, Claude ^a   Nemati, Fariba ^a   Poupon, Marie France ^a  

^a INSTITUT CURIE   (France)

Author keywords

ADEPT; Glucuronide; Phenol mustards; Prodrug

Indexed keywords

2 NITRO 4 HYDROXYMETHYLPHENOL; BETA GLUCURONIDASE; BUFFER; CARBON DIOXIDE; DIMETHYLIMIDAZOLIDINONE; GLUCURONIDE; MUSTARD GAS DERIVATIVE; PHENOL DERIVATIVE; PHOSPHATE; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CYCLIZATION; CYTOTOXICITY; DRUG DESIGN; DRUG ELIMINATION; DRUG HYDROLYSIS; DRUG STABILITY; DRUG SYNTHESIS; ESCHERICHIA COLI; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DESIGN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; GLUCURONATES; GLUCURONIDASE; HUMANS; HYDROLYSIS; MUSTARD COMPOUNDS; PHENOLS; PRODRUGS; TUMOR CELLS, CULTURED;

EID: 0032410355     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. AZOULAY, M., FLORENT, J.-C., MONNERET, C., GESSON, J.-P., JACQUESY, J.-C., TILLEQUIN, F., KOCH, M., BOSSLET, K., CZECH, J. & HOFFMAN, D. (1995). Prodrugs of anthracycline antibiotics suited for tumor-specific activation. Anti-Cancer Drug Design, 10, 441.
2. BAGSHAWE, K.D. (1987). Antibody-directed enzymes revive anti-cancer prodrugs concept. British Journal of Cancer, 56, 531.
3. BAGSHAWE, K.D. (1989). Towards generating cytotoxic agents at cancer sites. British Journal of Cancer, 60, 275.
4. BAGSHAWE, K.D. (1995). Antibody-Directed Enzyme Prodrug Therapy: a review. Drug Development Research, 34, 220.
5. BOLLENBACK, G.N., LONG, J.W., BENJAMIN, D.G. & LINDQUIST, J.A. (1995). The synthesis of aryl-D-glucopyranosiduronic acids. Journal of the American Chemical Society, 77, 3310.
6. BOSSLET, K., CZECH, J., LORENZ, P., SEDLACEK, H.H., SCHUERMANN, M. & SEEMANN, G. (1992). Molecular and functional characterisation of a fusion protein suited for tumor specific prodrug activation. British Journal of Cancer, 65, 234.
7. BOSSLET, K., CZECH, J. & HOFFMANN, D. (1994a). Tumor selective prodrug activation by fusion protein-mediated catalysis. Cancer Research, 54, 2151.
8. BOSSLET, K., CZECH, J., SEEMANN, G., MONNERET, C. & HOFFMANN, D. (1994b). Fusion protein mediated prodrug activation (FMPA) in vivo. Cell Biophysics, 24-25, 51.
9. BOSSLET, K., CZECH, J. & HOFFMANN, D. (1995). A novel one-step tumor-selective prodrug activation system. Tumor Targeting, 1, 45.
10. BOSSLET, K., STRAUB, R., BLUMRICH, M., CZECH, J., GERKEN, M., SPERKER, B., KROEMER, H.-K., GESSON, J.-P., KOCH, M. & MONNERET, C. (1998). Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Research, 58, 1195.
11. BURKE, P.J. (1996). Alkylation agent prodrugs for ADEPT. Advanced Drug Delivery Reviews, 22, 331.
12. BUTCHER, K.J. (1994). Carbamate esters: a simple, mild method of formation. Synlett, 825.
13. DEONARAIN, M.P. & EPENETOS, A.A. (1994). Targeting enzymes for cancer therapy: old enzymes in new roles. British Journal of Cancer, 70, 786.